FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Damm, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damm, K.

The FASEB Journal, Vol 7, 904-909, Copyright © 1993 by The Federation of American Societies for Experimental Biology

REVIEWS

ErbA: tumor suppressor turned oncogene?

K Damm
Department of Neuroendocrinology, Max-Planck-Institute of Psychiatry, Munich, Germany.

Cancer has been commonly linked to aberrant proliferation and a failure of the transformed cells to differentiate. Activated proto-oncogenes are thought to provide continuous proliferation signals that enhance the growth of these cells. Conversely, cellular transformation may also be achieved by the inactivation of genes whose normal function is to constrain cell growth by either suppressing proliferation or inducing differentiation. Such an inactivation could result from dominant- negative mutations, leading to the expression of abnormal proteins that inhibit the function of their normal counterparts. A prototype example is the v-erbA oncogene of the avian erythroblastosis virus (AEV), which antagonizes the transcriptional regulatory function of the chicken c- ErbA/thyroid hormone receptors (c-ErbA/TR) and the structurally related retinoic acid receptors (RARs). The result of this inhibition is a loss of hormone responsiveness and hormone-induced differentiation. Here we have a parallel to the tumor suppressor gene where it is also a loss of function that induces the transformation process. In this way, the normal, hormone-activated c-ErbA/TRs and RARs act as growth suppressors because the resulting differentiated cells irreversibly lose proliferative potential. In this article, the properties of v-ErbA will be discussed in the context of c-ErbA/thyroid hormone and retinoic acid receptor function.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
T. Takano, A. Miyauchi, H. Yoshida, Y. Nakata, K. Kuma, and N. Amino
Expression of TR{beta}1 mRNAs with Functionally Impaired Mutations Is Rare in Thyroid Papillary Carcinoma
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3447 - 3449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Onda, D. Li, S. Suzuki, I. Nakamura, S. Takenoshita, C.-H. Brogren, S. Stampanoni, and N. Rampino
Expansion of Microsatellite in the Thyroid Hormone Receptor-{alpha}1 Gene Linked to Increased Receptor Expression and Less Aggressive Thyroid Cancer
Clin. Cancer Res., September 1, 2002; 8(9): 2870 - 2874.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Puzianowska-Kuznicka, A. Krystyniak, A. Madej, S.-Y. Cheng, and J. Nauman
Functionally Impaired TR Mutants Are Present in Thyroid Papillary Cancer
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1120 - 1128.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.